|
|
NIAID Inventions Available for Licensing
A categorized list of technology abstracts from all of NIH is presented on the web site of the NIH Office of Technology Transfer (OTT), the central licensing office for all of NIH, including NIAID. The OTT abstract search engine may be used to identify abstracts of interest. You may also view all NIAID technologies presented by the OTT abstract search engine.
The abstracts linked on this page were available on the OTT web site on 28 November 2005.
Sections of this page
Technology Areas
General Technology Areas
Cancer
Central Nervous System
Devices/Instrumentation
Infectious Diseases
Internal Medicine
Specific Technologies
Cancer - Diagnostics
Cancer - Diagnostics-In Vitro-DNA Based
Cancer - Diagnostics-In Vitro-Other
Cancer - Diagnostics-In Vivo-MAb
Cancer - Research Materials
Cancer - Therapeutics
Cancer - Therapeutics-Biological Response Modifiers-Cytokines
Cancer - Therapeutics-Gene Therapy-Vectors
Cancer - Therapeutics-Immunoconjugates-Mab
Cancer - Therapeutics-Immunoconjugates-Toxins
Cancer - Therapeutics-Immunomodulators and Immunostimulants
Cancer - Therapeutics-Other
Cancer - Therapeutics-Vaccines
Central Nervous System - Therapeutics
Central Nervous System - Therapeutics-Neurological Therapeutics-Alzheimer
Devices/Instrumentation - Diagnostics
Devices/Instrumentation - Diagnostics-Imaging
Devices/Instrumentation - Research Materials
Devices/Instrumentation - Research Materials-Biologicals and Chemicals
Devices/Instrumentation - Research Materials-Devices-Chromatographic
Devices/Instrumentation - Research Materials-Methods of Using Research Tools
Devices/Instrumentation - Research Materials-Software
Devices/Instrumentation - Software
Devices/Instrumentation - Software-Data-base
Infectious Diseases - Diagnostics
Infectious Diseases - Diagnostics-Bacterial
Infectious Diseases - Diagnostics-Fungal
Infectious Diseases - Diagnostics-Parasitic
Infectious Diseases - Diagnostics-Viral
Infectious Diseases - Diagnostics-Viral-AIDS (only)
Infectious Diseases - Diagnostics-Viral-Non-AIDS (only)
Infectious Diseases - Other
Infectious Diseases - Research Materials
Infectious Diseases - Therapeutics
- A Novel Interleukin-12 (IL-12) Inducing Protein Isolated from Toxoplasma gondii Inflammatory Profilin (TGIP)
- Aerosolized Capreomycin for Inhibition of Pulmonary Tuberculosis
- Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof
- Anti-Plasmodium Compositions and Methods of Use
- Antibodies Against the Amino Terminus Region of Circumsporozoite Protein Prevent the Onset of Malaria
- Assays for Assembly of Ebola Virus Pseudoparticles Relevant to Antiviral Therapy and Vaccines
- CC Chemokine Receptor 5 DNA, New Animal Models and Therapeutic Agents for HIV Infection
- Cell Culture System for Efficient Expression of Self-Replicating Norwalk Virus
- Chimeric HIV/SIV Polypeptide Trimers as HIV/AIDS Vaccine Candidates
- Cloned Genomes Of Infectious Hepatitis C Virus And Uses Thereof
- Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome
- Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and Md145-12)
- Diagnostic Reagents And Vaccines For Multiple Genotypes Of Hepatitis C Virus
- Efficient Inhibition of HIV-1 Viral Entry Through a Novel Fusion Protein Including CD4
- Enhanced Sensitivity ELISA for SARS Diagnostic
- Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus)
- Eosinophil-Derived Neurotoxin, an Antimicrobial Protein with Ribonuclease Activity, is an Immunostimulant
- HIV Neutralization by Structure-Based Enhancements of CD4-Molecular Mimicry
- HTLV-1 Cell Binding and Inhibition
- Identification of a Fusion/Entry Receptor for Human Herpesvirus-8
- Identification of the Domain of Plasmodium falciparum Erythrocyte Membrane Protein (PfEMP1) that Mediates Adhesion to Chondroitin Sulfate A
- Inhibition of Diseases Associated with Amyloid Formation
- Inhibitors of Amyloid Formation
- Inhibitors of Formation of Protease Resistant Prion Protein
- Interferon-Alpha SARS Treatment
- Ixodes scapularis Tissue Factor Pathway Inhibitor
- Lutozmyia longipalpis Polypeptides and Methods of Use
- Mechanisms for Improving the Breadth of the Immune Response to Diverse Strains and Clades of HIV
- Method of Diagnosing Multidrug Resistant Tuberculosis
- Methods For Treating Parasitic Infection Using Thiopeptides
- Methods for Treating Viral-Associated Tumors with LFA-1 Inhibiting Statins
- Modulators of Nuclear Hormone Receptor Activity: Novel Compounds, Diverse Applications for Infectious Diseases, Including Anthrax (B. anthracis)
- MVA Expressing Modified HIV envelope, gag, and pol Genes
- North-2'-Deoxy-Methanocarbathymidines as Antiviral Agents Against Poxviruses
- Novel Anti-Mycobacterial Compositions and Their Use for the Treatment of Tuberculosis and Related Diseases
- Novel Spore Wall Proteins and Genes From Microsporidia
- Protozoan Derived Antagonist of CCR5
- Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection (E-250-2002)
- SARS Coronavirus MVA Vaccines and Therapy
- Soluble SARS Coronavirus Spike Protein (S Protein)
- Streptococcus Lipoprotein Antigens
Infectious Diseases - Therapeutics-Anti-Bacterial
Infectious Diseases - Therapeutics-Anti-Parasitic
Infectious Diseases - Therapeutics-Anti-Viral
Infectious Diseases - Therapeutics-Anti-Viral-AIDS (only)
Infectious Diseases - Therapeutics-Anti-Viral-Non-AIDS (only)
Infectious Diseases - Therapeutics-Other
Infectious Diseases - Vaccines
- A Novel Interleukin-12 (IL-12) Inducing Protein Isolated from Toxoplasma gondii Inflammatory Profilin (TGIP)
- A Universal Antigen Delivery Platform for Enhanced Immune Response
- Accelerated Vaccination Strategies to Provide Protection Against Viral Infections
- Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof
- Anti-Plasmodium Compositions and Methods of Use
- Antibodies Against the Amino Terminus Region of Circumsporozoite Protein Prevent the Onset of Malaria
- Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines
- Attenuated Human Rotavirus Vaccine
- Binding Domains from Plasmodium vivax and Plasmodium falciparum Erythrocyte Binding Proteins
- Candidate DNA HIV Vaccine
- Cellular Receptor for Varicella-Zoster Virus and Cell-to-Cell Spread of Virus
- Chimeric HIV/SIV Polypeptide Trimers as HIV/AIDS Vaccine Candidates
- Chondroitin Sulphate A Binding Domains: Potential Vaccine for Malaria
- Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof
- Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome
- Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and Md145-12)
- Construction of West Nile Virus and Dengue Virus Chimeras for Use in a Live Virus Vaccine to Prevent Disease Caused by West Nile Virus
- Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4
- Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses
- Efficient Inhibition of HIV-1 Viral Entry Through a Novel Fusion Protein Including CD4
- Enhanced Sensitivity ELISA for SARS Diagnostic
- Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus)
- Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) that Encodes Biologically Active Proteins
- Gene for Encoding a Human Malaria Vaccine Antigen
- HCV/BVDV Chimeric Genomes and Uses Thereof
- HIV gp41-Membrane Proximal Region Arrayed on Hepatitis B Surface Antigen Particles for HIV Diagnostic and Vaccine Applications
- HIV Neutralization by Structure-Based Enhancements of CD4-Molecular Mimicry
- HIV Vaccine Immunogens and Immunization Strategies
- HIV-Encoded siRNA, microRNA and Suppressor of RNA Silencing
- Identification of New Malaria Parasite Erythrocyte Binding Protein (BAEBL) that Binds to Human Red Cells
- Identification of the Domain of Plasmodium falciparum Erythrocyte Membrane Protein (PfEMP1) that Mediates Adhesion to Chondroitin Sulfate A
- Improved Non-Viral Mammalian Expression Vector
- Infectious cDNA Clone of GB Virus B and Uses Thereof
- Inhibition of HIV Replication in Resting CD4+ Lymphocytes by Murr1
- Ixodes scapularis Tissue Factor Pathway Inhibitor
- Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus
- Lutozmyia longipalpis Polypeptides and Methods of Use
- Malarial Immunogen
- Mechanisms for Improving the Breadth of the Immune Response to Diverse Strains and Clades of HIV
- Methods for Treating Viral-Associated Tumors with LFA-1 Inhibiting Statins
- Modifications of HIV Env, Gag and Pol Enhance Immunogenicity for Genetic Immunization
- Monoclonal Antibodies Specific for the E2 Glycoprotein of Hepatitis C Virus and Their Use in the Diagnosis, Treatment and Prevention of Hepatitis C
- Mucosal Cytotoxic T Lymphocyte Responses
- Multivalent Human-Bovine Rotavirus Vaccine
- MVA Expressing Modified HIV envelope, gag, and pol Genes
- Novel Attenuated Strains of Mycobacterium Tuberculosis
- Novel HIV Related Peptides
- Nucleotide And Deduced Amino Acid Sequences Of The Envelope-1 And Core Genes Of Isolates Of Hepatitis C Virus And Methods Of Use
- Oligomeric HIV-1 Envelope Glycoproteins
- Recombinant DNA Clone Containing a Genomic Fragment of PfHRP-II Gene from Plasmodium falciparum
- Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development
- Recombinant Proteins of the Swine Hepatitis E Virus and Their Uses as a Vaccine and Diagnostic Reagents for Medical and Veterinary Applications
- Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection
- Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection (E-217-2004)
- Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection (E-250-2002)
- SARS Coronavirus MVA Vaccines and Therapy
- Soluble SARS Coronavirus Spike Protein (S Protein)
- Streptococcus Lipoprotein Antigens
- Synthetic Vaccine Against P. falciparum Malaria
- Target Antigens of Transmission Blocking Antibodies for Malaria Parasites
- Transmission-Blocking Vaccine Against Malaria (1)
- Transmission-Blocking Vaccine Against Malaria (2)
- VAC-BAC Shuttle Vector System
- Vaccines For Blocking Transmission of Plasmodium vivax
Infectious Diseases - Vaccines-Adjuvants/Vectors/Modulators
Infectious Diseases - Vaccines-Bacterial
Infectious Diseases - Vaccines-Other
Infectious Diseases - Vaccines-Parasitic
Infectious Diseases - Vaccines-Viral
Infectious Diseases - Vaccines-Viral-AIDS (only)
Infectious Diseases - Vaccines-Viral-Non-AIDS (only)
Internal Medicine - Diagnostics
Internal Medicine - Other
Internal Medicine - Research Materials
Internal Medicine - Therapeutics
Internal Medicine - Therapeutics-Anti-Inflammatory (including Autoimmune)
Internal Medicine - Therapeutics-Pulmonary
back to top |
|
|
|